SPG78 HSP mechanism investigated

Posted - February 2017 in Research Highlights

Pathway leads to sell organelle impairment

 

HSP associated mutations in the ATP13A2 gene lead to impairment of the function of both lysosomes and mitochondria via a pathway described in detail in this study. These mutations are generally associated with complicated HSP with a wide range of symptom severity.

 

Other mutations in this gene are associated with Spastic Ataxia, juvenile onset Parkinsonism and Kufor-Rakeb syndrome.

 

Dr. Rebecca Schüle

Hereditary spastic paraplegias are heterogeneous neurodegenerative disorders characterized by progressive spasticity of the lower limbs due to degeneration of the corticospinal motor neurons. In a Bulgarian family with three siblings affected by complicated hereditary spastic paraplegia, we performed whole exome sequencing and homozygosity mapping and identified a homozygous p.Thr512Ile (c.1535C > T) mutation in ATP13A2.

 

Molecular defects in this gene have been causally associated with Kufor-Rakeb syndrome (#606693), an autosomal recessive form of juvenile-onset parkinsonism, and neuronal ceroid lipofuscinosis (#606693), a neurodegenerative disorder characterized by the intracellular accumulation of autofluorescent lipopigments. Further analysis of 795 index cases with hereditary spastic paraplegia and related disorders revealed two additional families carrying truncating biallelic mutations in ATP13A2. ATP13A2 is a lysosomal P5-type transport ATPase, the activity of which critically depends on catalytic autophosphorylation.

 

Our biochemical and immunocytochemical experiments in COS-1 and HeLa cells and patient-derived fibroblasts demonstrated that the hereditary spastic paraplegia-associated mutations, similarly to the ones causing Kufor-Rakeb syndrome and neuronal ceroid lipofuscinosis, cause loss of ATP13A2 function due to transcript or protein instability and abnormal intracellular localization of the mutant proteins, ultimately impairing the lysosomal and mitochondrial function.

 

Moreover, we provide the first biochemical evidence that disease-causing mutations can affect the catalytic autophosphorylation activity of ATP13A2. Our study adds complicated hereditary spastic paraplegia (SPG78) to the clinical continuum of ATP13A2-associated neurological disorders, which are commonly hallmarked by lysosomal and mitochondrial dysfunction.

 

The disease presentation in our patients with hereditary spastic paraplegia was dominated by an adult-onset lower-limb predominant spastic paraparesis. Cognitive impairment was present in most of the cases and ranged from very mild deficits to advanced dementia with fronto-temporal characteristics. Nerve conduction studies revealed involvement of the peripheral motor and sensory nerves. Only one of five patients with hereditary spastic paraplegia showed clinical indication of extrapyramidal involvement in the form of subtle bradykinesia and slight resting tremor. Neuroimaging cranial investigations revealed pronounced vermian and hemispheric cerebellar atrophy. Notably, reduced striatal dopamine was apparent in the brain of one of the patients, who had no clinical signs or symptoms of extrapyramidal involvement.

 

SOURCE: Brain. 2017 Feb;140(Pt 2):287-305. doi: 10.1093/brain/aww307. PMID: 28137957 PMCID: PMC5278306 [Available on 2018-02-01] [PubMed – in process] © The Author (2016). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: [email protected]

 

Loss-of-function mutations in the ATP13A2/PARK9 gene cause complicated hereditary spastic paraplegia (SPG78).

 

Estrada-Cuzcano A1, Martin S2, Chamova T3, Synofzik M4,5, Timmann D6, Holemans T2, Andreeva A3, Reichbauer J4, De Rycke R7, Chang DI7, van Veen S2, Samuel J3, Schöls L4,5, Pöppel T8, Mollerup Sørensen D2, Asselbergh B9, Klein C1,1, Zuchner S1, Jordanova A1,1,2, Vangheluwe P2, Tournev I3,1,3, Schüle R10,5,1.

 

1 Molecular Neurogenomics Group, VIB Department of Molecular Genetics, University of Antwerp, Universiteitsplein 1, 2610 Antwerpen, Belgium.

2 Laboratory of Cellular Transport Systems, Department of Cellular and Molecular Medicine, KU Leuven; 3000 Leuven, Belgium.

3 Department of Neurology, Medical University-Sofia, 1431 Sofia, Bulgaria.

4 Center for Neurology and Hertie Institute for Clinical Brain Research, University of Tübingen, 72076 Tübingen, Germany.

5 German Center of Neurodegenerative Diseases (DZNE), 72076 Tübingen, Germany.

6 Department of Neurology, Essen University Hospital, University of Duisburg-Essen, 45147 Essen, Germany.

7 Inflammation Research Center, VIB, Ghent, Belgium and Department of Biomedical Molecular Biology, Ghent University, 9052 Ghent, Belgium.

8 Department of Nuclear Medicine, Essen University Hospital, University of Duisburg-Essen, 45147 Essen, Germany.

9 VIB Department of Molecular Genetics, University of Antwerp, Universiteitsplein 1, 2610 Antwerpen, Belgium.

10 Center for Neurology and Hertie Institute for Clinical Brain Research, University of Tübingen, 72076 Tübingen, Germany [email protected] [email protected]

 

Add your comment on this story